Cagrilintide is an amylin analog investigated for its role in appetite regulation and glucose control. Research focuses on its potential to reduce food intake, promote weight loss, and improve metabolic health, with applications in obesity and diabetes management.
Molecular Formula: C₁₉₄H₃₁₂N₅₄O₅₉S₂
Molecular Weight: 4409.01 g/mol
Purity: 99%
For research purposes only. This product is supplied exclusively for scientific laboratory research and analytical purposes. It is not intended for human or animal use, and must not be misused in any way that contravenes MHRA regulations or applicable laws.
Cagrilinitide (or “Cagri”) is a long-acting, lipidated, albumin-binding amylin agonist that targets both amylin and calcitonin receptors. It is used in the treatment of obesity, either on its own or in combination with GLP-1 receptor agonists. Amylin is co-secreted with insulin from pancreatic beta cells and regulates appetite, satiety, gastric emptying, and glucose control.
Combining Cagrilinitide with a GLP-1 like Semaglutide has a synergistic effect, amplifying weight loss beyond what either peptide achieves independently. Other benefits include improved circulation, reduced blood pressure, enhanced bone-building activity, and vasodilation.
Outcomes
6–10% body weight loss at 26 weeks (Cagrilinitide alone)
23–24.4% body weight loss at 68 weeks (combined with Semaglutide)
Synergistic effect: up to 8% more weight loss vs. Semaglutide alone
Possible Side Effects
Injection site reaction (redness, swelling, itching, hives)
This website uses cookies to improve your experience. By clicking “Deny”, you consent to the use of Necessary cookies only. You may also accept selected cookies only.
